Although the BTK is not a MYD88 (L265P)-specific target and is not directly involved with the MYD88-derived protein complex, inhibition of BTK has been widely studied and revealed as the most successful therapy in CLL [71]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.